Patent ID: 9080216
Filing Date: 2015-07-14
Classification: A61K,A61P,C12Q,G01N

Abstract:
1. A method of identifying a patient suffering from a cancer which is likely to be refractory to radiation therapy comprising: (i) identifying an 11q deletion in a patient sample considered to be representative of the cancer by a method selected from the group consisting of fluorescence in situ hybridization, quantitative microsatellite analysis, and loss of heterozygosity analysis; (ii) identifying, in the patient sample, overexpression of a gene selected from the group consisting of ATR, CEK1, CCND1, and a combination thereof by a method selected from the group consisting of quantitative reverse transcriptase PCR, Western blot, and fluorescence in situ hybridization; and (iii) identifying, in the patient sample, a decrease or absence of p53 expression and/or activity by a method selected from the group consisting of quantitative reverse transcriptase PCR and Western blot, wherein an 11q deletion, overexpression of ATR, CHEK1, CCND1, or a combination thereof, and a decrease or absence of p53 expression and/or activity indicates that the cancer is likely to be refractory to radiation therapy and may benefit from inhibition of the ATR/CHEK1 pathway, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, breast carcinoma, ovarian carcinoma, lung carcinoma, multiple myeloma cancer, and prostate cancer.